Esperite N.V. and Myrisoph Capital Inc. announced that they have concluded a strategic agreement related to Cryo-Save’s stem cell cryopreservation business. Myrisoph becomes the exclusive global licensee of the CryoSave brand for a minimum period of ten (10) years. Along with Cryo-Save’s long-established quality history and service, the transaction leverages Myrisoph Capital’s experience and success in turning around Medical, Laboratory and Biotech companies 'including Cryo-Save Arabia, the first Stem Cell Bank in the Middle-East and North Africa region, and currently one of the more profitable cord blood banks worldwide.